Active Ingredient History
Motexafin gadolinium is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain metastases. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Adenocarcinoma (Phase 2)
Astrocytoma (Phase 1)
Bile Duct Neoplasms (Phase 1)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 1)
Carcinoma, Bronchogenic (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 2)
Colorectal Neoplasms (Phase 1)
Gallbladder Neoplasms (Phase 1)
Gastrointestinal Neoplasms (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Head and Neck Neoplasms (Phase 1)
Intestinal Neoplasms (Phase 1)
Kidney Neoplasms (Phase 2)
Laryngeal Neoplasms (Phase 1)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 2)
Myeloproliferative Disorders (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Oligodendroglioma (Phase 1)
Oropharyngeal Neoplasms (Phase 1)
Ovarian Neoplasms (Phase 1)
Pancreatic Neoplasms (Phase 1)
Prostatic Neoplasms (Phase 1)
Urogenital Neoplasms (Phase 2)
Urologic Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue